Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other condit...

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.
...

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-
Clinical Trials
Related News

Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A

First Posted Date
2022-07-20
Last Posted Date
2024-05-14
Lead Sponsor
Emory University
Target Recruit Count
42
Registration Number
NCT05466539
Locations
🇺🇸

Emory Sports Medicine-Dunwoody, Atlanta, Georgia, United States

🇺🇸

Emory Hawks Sports Medicine Center, Brookhaven, Georgia, United States

The Effect of Subcutaneous Injection of Botulinum Toxin A on Chronic Wound Pain in Lower Extremities

Phase 4
Completed
Conditions
Chronic Pain
Lower Extremity Wound
Interventions
Drug: Botulinum Toxin A
First Posted Date
2022-06-21
Last Posted Date
2024-08-09
Lead Sponsor
Bispebjerg Hospital
Target Recruit Count
10
Registration Number
NCT05426161
Locations
🇩🇰

Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital, Copenhagen, Denmark

Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity

Not yet recruiting
Conditions
Spasticity as Sequela of Stroke
Interventions
Drug: Botulinum toxin type A
First Posted Date
2022-05-18
Last Posted Date
2022-05-23
Lead Sponsor
Campus Bio-Medico University
Target Recruit Count
960
Registration Number
NCT05379413
Locations
🇮🇹

ASL RM 1 San Filippo Neri Hospital, Roma, Lazio, Italy

🇮🇹

Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Lazio, Italy

🇮🇹

Sapienza University of Rome - Stroke Unit, Roma, Lazio, Italy

and more 1 locations

The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis

First Posted Date
2022-05-10
Last Posted Date
2024-09-30
Lead Sponsor
Western Institute for Veterans Research
Target Recruit Count
62
Registration Number
NCT05367271
Locations
🇺🇸

VA Salt Lake City Health Care System, Salt Lake City, Utah, United States

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Early Phase 1
Active, not recruiting
Conditions
Keloid
Interventions
Drug: Vehicle
Drug: Botulinum toxin type A
First Posted Date
2022-04-15
Last Posted Date
2023-05-03
Lead Sponsor
University of California, San Diego
Target Recruit Count
10
Registration Number
NCT05330078
Locations
🇺🇸

University of California San Diego, San Diego, California, United States

A Study of Botulinum Toxin Type A Treatment of Wrinkles in Asian

Early Phase 1
Completed
Conditions
Botulinum Toxin, Type A
Interventions
Drug: Botulinum toxin type A
First Posted Date
2022-04-12
Last Posted Date
2022-04-12
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
250
Registration Number
NCT05324839

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

First Posted Date
2022-04-11
Last Posted Date
2023-09-07
Lead Sponsor
Evolus, Inc.
Target Recruit Count
153
Registration Number
NCT05320393
Locations
🇺🇸

Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida, United States

Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter

Not Applicable
Completed
Conditions
Bite Force
Botulinum Toxins, Type A
Interventions
Drug: Botulinum toxin type A
First Posted Date
2022-04-04
Last Posted Date
2023-05-03
Lead Sponsor
Region Västerbotten
Target Recruit Count
32
Registration Number
NCT05309564
Locations
🇸🇪

Norrlands universitetssjukhus, Umeå, Västerbotten, Sweden

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

Early Phase 1
Conditions
Glabellar Frown Lines
Interventions
Drug: IncobotulinumtoxinA
First Posted Date
2022-03-31
Last Posted Date
2022-03-31
Lead Sponsor
Clinical Testing of Beverly Hills
Target Recruit Count
40
Registration Number
NCT05305768
Locations
🇺🇸

Clinical Testing of Beverly Hills, Encino, California, United States

🇺🇸

Alexander Rivkin MD, Los Angeles, California, United States

Botulinum Toxin Type A in Diabetic Peripheral Neuropathy

First Posted Date
2022-03-25
Last Posted Date
2022-04-06
Lead Sponsor
Alexandria University
Target Recruit Count
30
Registration Number
NCT05296759
Locations
🇪🇬

faculty of medicine Alexandria university, Alexandria, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy